The study was a single center observational-prospective study and approved by local ethics committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic stroke who are older than 18 years of age were included in the study. Patients who received amantadine 200mg/day for fourteen days according to ICU protocols decided by primary physician formed the amantadine group, and the rest of the subjects were included in the control group. All patients were evaluated for Glasgow Coma Score, JFK Coma Recovery Scale and Disability Rating Scale once a week for three months.

Inclusion Criteria:

• ≥18 years, ≤ 65 years
• GCS score ≤ 8
• Coma state due to ischemic stroke, brain hemorhage, anoxic brain damage

Exclusion Criteria:

• <18 years, > 65 years
• Patients admitted to the critical care without diagnosis of coma state
• Patients admitted to critical care with coma state that are not duo to ischemic stroke, brain hemorhage, anoxic brain damage
• Metastatic malignant neoplazm
• Congenital or acquired brain function problem (cerebral palsy, autism etc)
• Patients with amantadine allergy
• Progressive degenerative diseases (Alzheimer, Parkinson diseases etc)

Patients with the coma state duo to ischemic stroke, brain hemorhage, anoxic brain damage included in this study.